Biological Factors
Kyowa Kirin Invests $530M in First North American Biologics Manufacturing Facility
Kyowa Kirin, biologics manufacturing, North America, investment, North Carolina
Bionova Scientific Expands into Plasmid DNA Services for Cell and Gene Therapy Developers
Bionova Scientific, Plasmid DNA, Cell and Gene Therapy, CDMO, Asahi Kasei Group, Biopharmaceuticals, Biologics, Texas Facility
Miniature Swine: Revolutionizing Nonclinical Studies for Small Molecules and Biologics
Miniature swine, Nonclinical studies, Small molecules, Biologics, Dermal testing, Safety assessments, Research models
Immunovant Shifts Focus to Next-Generation FcRn Inhibitor IMVT-1402, Delaying Batoclimab Development ###
Immunovant, IMVT-1402, FcRn inhibitor, Batoclimab, Autoimmune diseases, Vyvgart, Roivant, Biopharmaceuticals
Innovent Biologics’ Picankibart Achieves Success in Phase III CLEAR-1 Study for Moderate to Severe Plaque Psoriasis
Innovent Biologics, picankibart, Phase III CLEAR-1 study, moderate to severe plaque psoriasis, IL-23p19 class, new drug application, Center for Drug Evaluation, National Medical Product Administration.
Revolutionizing Biotherapeutic Analysis: Novel icIEF Fractionation and Mass Spectrometry for Charge Characterization
biotherapeutics, icIEF fractionation, mass spectrometry, charge characterization, protein analysis, therapeutic proteins, biopharmaceuticals, analytical techniques, protein purification, protein separation, protein charge variants.
Tremfya Emerges as a Promising Successor to Stelara in J&J’s Pipeline with Robust Clinical Data
J&J, Tremfya, Stelara, successor, head-to-head data, clinical trials, psoriasis treatment, biologics.
FDA Greenlights Biocon Biologics and Biogen’s Eylea Biosimilars: A New Era in Ophthalmology
FDA, Eylea, biosimilars, Biocon Biologics, Biogen, ophthalmology, aflibercept, regulatory approval
Johnson & Johnson Expands into IL-13 and TSLP Market with Strategic Acquisition
Johnson & Johnson, I&I acquisition, IL-13, TSLP, competitive market, strategic expansion, pharmaceutical industry, biologics, inflammatory diseases.
Innovent Scores Phase 3 Success with Lilly’s Pioneering Obesity Drug for Diabetes Management
Innovent Biologics, Eli Lilly, obesity drug, diabetes management, phase 3 trials, collaboration, metabolic disorders, weight loss, glucose control, next-generation therapy.